ANI Pharmaceuticals is rated Buy at ~$80, with a 12-month fair value set at $95, as the current valuation undervalues 2027 earnings potential. 2026 results are depressed by upfront gout expansion costs and higher Corticotrophin royalties, but revenue and operating leverage from these investments are expected to materialize in 2027. Most 2026 Cortrophin growth is projected from established indications, not the new gout initiative, which is viewed as a 2027 upside driver.